Core Biogenesis (Founders Program) raises 10M€ to accelerate treatment against cancer and neurodegenerative diseases

Core Biogenesis is stepping forward to the next level. After a first seed raise of 2,6M€ in December 2020, the company part of STATION F’s Founders Program announced a 10M€ Series A raise with XAnge and Blue Horizon Ventures to accelerate treatment against cancer and neurodegenerative diseases.

Created in 2020 by Dr Chouaib Meziadi and Alexandre Reeber, Core Biogenesis uses plants as biofactories to scale the production of high-value bioproducts. The company has built a platform accelerating mass production and increasing yields, while driving down costs. The molecules produced by Core Biogenesis are a key element in the production of cell and gene therapies.

This new fundraising will allow the company, which is planning to commercialize its molecules at the beginning of 2023, to grow to an industrial scale with a factory and hire about 10 scientific profiles during the next 6 months to grow its team to 30 people.

“After several months of research and development and laboratory production, we’re opening a new phase with the industrialization of our bioproduction technology. Our goal is to be the world’s leader in this new market at the crossroads of health, biopharma and biotech”, explained the co-founders of Core Biogenesis Alexandre Reeber and Chouaib Meziadi.

Want to grow your startup? Apply to one of STATION F’s startup programs here.